SNOA - オクルス・イノベイティブ・サイエンス (Sonoma Pharmaceuticals Inc.)

SNOAのニュース

   Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2020 Financial Results  2020/07/10 21:00:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions today announced financial results for fiscal year 2020 and the fourth quarter ended March 31, 2020. “We began this fiscal year with a goal of reducing our losses and cash burn and are pleased with an 75% drop in our net loss whil
   Sonoma Pharmaceuticals : Annual report pursuant to Section 13 and 15(d) | MarketScreener  2020/07/10 20:16:04 MarketScreener
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form… | July 10, 2020
   Sonoma Pharmaceuticals stock nearly triples after disinfectant allowed to carry COVID-19 label in Australia  2020/05/29 12:20:38 MarketWatch
Shares of Sonoma Pharmaceuticals Inc. undefined nearly tripled on heavy volume in premarket trading Friday, after the California-based producer of…
   Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Received Approval to Be Entered Into the Australian Register of Therapeutic Goods (ARTG) for use against COVID-19  2020/05/28 20:30:00 Business Wire
PETALUMA, Calif.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions, and its partner, the MicroSafe Group, Dubai, announce an important break-through in the fight of the global coronavirus pandemic. MicroSafe Care Australia received approval for their patented and trademarked Nanocyn® Disinfect
   Sonoma Pharmaceuticals Announces Expanded Distribution Agreement with Brill International S.L. for Europe and approval of new CE Marking for Microdacyn60® Eye Care  2020/05/26 20:57:00 Business Wire
PETALUMA, Calif.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions, is pleased to announce that it received a new CE Marking (Conformité Européenne) for its Microdacyn60® Eye Care based on Sonoma’s patented Microcyn® Technology. The formulation, marketed in the United States as Acuicyn™ Antimi
   Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2020 Financial Results  2020/07/10 21:00:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions today announced financial results for fiscal year 2020 and the fourth quarter ended March 31, 2020. “We began this fiscal year with a goal of reducing our losses and cash burn and are pleased with an 75% drop in our net loss whil
   Sonoma Pharmaceuticals : Annual report pursuant to Section 13 and 15(d) | MarketScreener  2020/07/10 20:16:04 MarketScreener
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form… | July 10, 2020
   Sonoma Pharmaceuticals stock nearly triples after disinfectant allowed to carry COVID-19 label in Australia  2020/05/29 12:20:38 MarketWatch
Shares of Sonoma Pharmaceuticals Inc. undefined nearly tripled on heavy volume in premarket trading Friday, after the California-based producer of…
   Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Received Approval to Be Entered Into the Australian Register of Therapeutic Goods (ARTG) for use against COVID-19  2020/05/28 20:30:00 Business Wire
PETALUMA, Calif.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions, and its partner, the MicroSafe Group, Dubai, announce an important break-through in the fight of the global coronavirus pandemic. MicroSafe Care Australia received approval for their patented and trademarked Nanocyn® Disinfect
   Sonoma Pharmaceuticals Announces Expanded Distribution Agreement with Brill International S.L. for Europe and approval of new CE Marking for Microdacyn60® Eye Care  2020/05/26 20:57:00 Business Wire
PETALUMA, Calif.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions, is pleased to announce that it received a new CE Marking (Conformité Européenne) for its Microdacyn60® Eye Care based on Sonoma’s patented Microcyn® Technology. The formulation, marketed in the United States as Acuicyn™ Antimi
   Sonoma Pharmaceuticals stock nearly triples after disinfectant allowed to carry COVID-19 label in Australia  2020/05/29 12:20:38 MarketWatch
Shares of Sonoma Pharmaceuticals Inc. undefined nearly tripled on heavy volume in premarket trading Friday, after the California-based producer of…
   Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Received Approval to Be Entered Into the Australian Register of Therapeutic Goods (ARTG) for use against COVID-19  2020/05/28 20:30:00 Business Wire
PETALUMA, Calif.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions, and its partner, the MicroSafe Group, Dubai, announce an important break-through in the fight of the global coronavirus pandemic. MicroSafe Care Australia received approval for their patented and trademarked Nanocyn® Disinfect
   Sonoma Pharmaceuticals Announces Expanded Distribution Agreement with Brill International S.L. for Europe and approval of new CE Marking for Microdacyn60® Eye Care  2020/05/26 20:57:00 Business Wire
PETALUMA, Calif.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions, is pleased to announce that it received a new CE Marking (Conformité Européenne) for its Microdacyn60® Eye Care based on Sonoma’s patented Microcyn® Technology. The formulation, marketed in the United States as Acuicyn™ Antimi
   Sonoma Pharmaceuticals : Prospectus filed pursuant to Rule 424(b)(3) | MarketScreener  2019/11/27 11:18:09 MarketScreener
Filed Pursuant to Rule 424 Registration No. 333-221477 PROSPECTUS SUPPLEMENT 448,949 shares of… | November 27, 2019
   Sonoma Pharma readies equity offering; shares down 15% premarket  2019/11/26 11:42:18 Seeking Alpha
Sonoma Pharmaceuticals (SNOA) launches a public offering of common shares. Price, volume and terms have yet to be announced. Net proceeds will be used for

calendar